New insights on pneumococcal disease: what we have learned over the past decade.
Since the introduction of the seven-valent pneumococcal conjugate vaccine (PCV7) in 2000, significant reductions in the rate of invasive pneumococcal diseases (IPDs) and mucosal infections caused by vaccine-specific serotypes have been observed in the targeted population (children aged <5 years). IPD rates have also decreased in adults aged >/=65 years, suggesting the extension of vaccine protection to the unimmunized population. A concomitant decline has been noted in antibiotic-resistant Streptococcus pneumoniae isolates. The incidence of vaccine-serotype IPD varies widely in geographically disparate regions, indicating that serotype coverage alone may not accurately predict the impact of proposed pneumococcal conjugate vaccines with additional serotypes.
Dagan
Ron
R
Pediatric Infectious Disease Unit, Soroka University Medical Center and the Faculty of Health Sciences, Ben-Gurion University of the Negev, P.O. Box 151, Beer-Sheva 84101, Israel. rdagan@bgu.ac.il
D002675:Child, Preschool; D024881:Drug Resistance, Bacterial; D000069443:Heptavalent Pneumococcal Conjugate Vaccine; D006801:Humans; D015994:Incidence; D011008:Pneumococcal Infections / Q000453:epidemiology* / Q000517:prevention & control; D022242:Pneumococcal Vaccines / Q000008:administration & dosage; D011159:Population Surveillance; D012703:Serotyping; D013296:Streptococcus pneumoniae / Q000145:classification / Q000187:drug effects; D018074:Vaccines, Conjugate / Q000008:administration & dosage
D000069443:Heptavalent Pneumococcal Conjugate Vaccine; D022242:Pneumococcal Vaccines; D018074:Vaccines, Conjugate